MegaPro Biomedical Co., Ltd (6827.TWO)

TWD 9.36

(-1.16%)

Market Cap (In TWD)

605.78 Million

Revenue (In TWD)

18 Thousand

Net Income (In TWD)

-127.54 Million

Avg. Volume

40.29 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13.0-29.6
PE
-3.49
EPS
-2.68
Beta Value
0.0
ISIN
TW0006827009
CUSIP
-
CIK
-
Shares
64720900.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jassy Wang
Employee Count
-
Website
https://www.megaprobio.com
Ipo Date
2021-10-19
Details
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.